Inspire Medical Systems stock snapshot

Inspire Medical Systems (INSP) focuses on minimally invasive devices for obstructive sleep apnea, and its stock has been under pressure, with shares down about 5% over the past month and 30% over the past 3 months.

The recent 4.0% 7-day share price gain has not reversed the longer slide, with the 1-year total shareholder return down 69.1%. Momentum still appears weak despite the short-term buying interest.

If you are comparing Inspire Medical Systems to other healthcare and medtech ideas, this could be a useful time to broaden your watchlist with 39 healthcare AI stocks

With the stock down sharply over the past year but trading below some analysts’ price targets and certain intrinsic value estimates, some investors may ask whether Inspire Medical Systems is now undervalued or whether the market is already pricing in its future growth.

Most Popular Narrative: 19.1% Undervalued

Inspire Medical Systems' most followed narrative pegs fair value at about $52.17 a share, above the last close of $42.21, framing the current discount as meaningful rather than marginal.

The recent delay in transitioning centers to the Inspire V next-generation system, including slower onboarding, delayed SleepSync implementation, and the Medicare billing update, are transitory issues; as these barriers resolve (with Medicare billing now live and most centers expected to complete onboarding by end of Q3), procedure volumes and revenue growth are positioned to reaccelerate in 2026 as pent-up demand is realized.

Want to understand why a slower earnings path still supports a higher fair value than the market price? The narrative leans on modest revenue growth assumptions, slimmer margins, and a richer future earnings multiple to justify that $52.17 figure. Curious which trade off between growth, profitability, and discount rate underpins that call and how sensitive the outcome is to those inputs? The full narrative lays out the complete playbook behind this valuation.

Result: Fair Value of $52.17 (UNDERVALUED)

However, you also need to weigh the risk that a slower Inspire V rollout and prolonged reimbursement or coding uncertainty could delay the earnings path behind this fair value story.

Wall Street's queuing for one rocket. While SpaceX counts down to its IPO, other companies tied to the new space race are already in orbit. → 20 Compelling Space Companies watchlist · Global Space Race Investing Ideas screener · Scan the sector by valuation on Rocket Lab's valuation page.

Next Steps

Given the mix of concerns and potential upside running through this story, it makes sense to move quickly and weigh the evidence yourself using the 4 key rewards and 2 important warning signs.

Ready to widen your opportunity set?

If Inspire Medical Systems has caught your attention, do not stop here. Use this moment to broaden your watchlist with ideas tailored to different investing goals.

• Spot potential bargains early by scanning the screener containing 21 high quality undiscovered gems that align strong fundamentals with limited market attention.
• Prioritize resilience by focusing on companies in the 63 resilient stocks with low risk scores that pair more stable profiles with lower risk scores.
• Strengthen your core holdings by reviewing stocks in the solid balance sheet and fundamentals stocks screener (46 results) that combine financial resilience with consistent fundamentals.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.